Market Intelligence, Clinical Progress, and High-Purity Reagents for Ribosomopathies and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RPS19 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RPS19 Recombinant Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RPS19 Products |
| Gene Delivery | RPS19 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and rescue assays. |
View RPS19 Products |
| Benchmark Ab | Anti-RPS19 Recombinant Antibody Recombinant positive control for target verification. |
View RPS19 Products |
| Validator | RPS19 siRNA Set For knockdown and specificity verification. |
View RPS19 Products |
| Related Target A | FPR2 (Formyl Peptide Receptor 2) Extracellular receptor for cross-linked RPS19, mediating anti-inflammatory signaling. |
View FPR2 Products |
| Related Target B | TLR2 (Toll-like Receptor 2) Interacts with extracellular RPS19 to drive immunosuppressive macrophage polarization in tumors. |
View TLR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating intracellular ribosomal roles from extracellular signaling | Human recombinant WT and mutant proteins available with high purity (>95%) for binding assays |
| Diamond-Blackfan Anemia (DBA) mutation modeling | Custom mutant proteins (e.g., R62W, V15F) sequence-verified for rescue and translation assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and validated controls included |
| False Positives | Validated siRNA sets included for target knockdown and specificity checks |
Live RPS19 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding RPS19 is bifurcated into two distinct, high-value pathways: gene therapy/gene editing to address loss-of-function mutations in Diamond-Blackfan Anemia (DBA), and targeted inhibition (both small molecules and monoclonal antibodies) to block extracellular RPS19-mediated immunosuppression in oncology. As first-generation gene therapies enter early clinical evaluation, oncology R&D is rapidly pivoting toward blocking the extracellular RPS19-FPR2/TLR2 signaling axes to reverse tumor-associated macrophage (TAM) immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (Lentiviral/CRISPR) | Academic Consortia, Rare Disease Biotechs | Diamond-Blackfan Anemia (DBA) | Transduction and expression verification (Need high-titer Lentivirus & mutant controls) |
| Monoclonal Antibodies | Oncology-focused Biopharma | Solid Tumors (Breast, Colon, Lung) | Blocking assays for extracellular RPS19-receptor interactions (Need pure WT protein & receptor targets) |
| Small Molecule Inhibitors | Ribosome Biogenesis Biotechs | Advanced Solid Tumors | In vitro translation and ribosomal assembly assays (Need sequence-verified active proteins) |